Publication
SAT1 promotes prostate cancer progression and decreases enzalutamide sensitivity by enhancing spermine catabolism.
Yixin Qu, Shengqiang Zhou, Yuanyuan Li, Jinfeng Duan, Han Zhang, Biqi Nie, Tao Hong, Xiaoxia Dong, Chunli Chen
Human cellSep 15, 2026PMID 42744967doi:10.1007/s13577-026-01453-6 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 17, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260917-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Prostate cancer is a major contributor to cancer-related mortality in men, and enzalutamide is a primary treatment option for advanced prostate cancer. Polyamines are ubiquitous amine molecules involved in tumorigenesis, cancer development, and drug resistance. This study aims to explore how…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.